Compare SOLAI Limited (SLAI) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SOLAI Limited vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? SOLAI Limited trades at $3.72 (market cap $880.09M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.7 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 2.6× SOLAI Limited's market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| SLAI | SLS | |
|---|---|---|
Market Cap | $880.09M | $2.27B |
Volume | 122,720 | 4,179,659 |
Sector | Technology | Health |
52-Week High | $21.63 | $15.46 |
52-Week Low | $2.74 | $1.39 |
Typical Hold Time | 40 Days | — |
Enterprise Value | $879.73M | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SLAI trades at $3.72 with no recent price movement. The technical picture is bullish based on moving averages and oscillators, though the stock faces delisting proceedings from the NYSE. Fundamentally, the company shows severe distress with negative gross and net income margins, high revenue decline, and substantial losses despite a low P/B ratio. Recent news highlights governance changes amid exchange compliance issues.
The outlook is highly risky due to financial instability and delisting threat. Investment opportunity exists only for speculative traders betting on a turnaround, given the low valuation multiple. Key risks include continued cash burn, inability to achieve profitability, and loss of major exchange listing impacting liquidity and investor confidence.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
